{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:31:20Z","timestamp":1789500680948,"version":"build-2803163510"},"reference-count":41,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>CA19.9 is a monosialoganglioside secreted by mucinous tumours of the gastrointestinal tract, including the pancreas and biliary tree. Limited studies have shown that this tumour marker may also be elevated in primary ovarian mucinous neoplasms, but no study has assessed whether serum CA19.9 levels can be used to predict if a primary ovarian mucinous tumour is benign, borderline or malignant. The aim of this study was to correlate the serum CA19.9 level with the histological features in a large series of primary ovarian mucinous neoplasms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>144 cases of primary ovarian mucinous neoplasm (79 benign, 45 borderline and 20 malignant) were identified in which a preoperative serum CA19.9 level had been performed. The association between the serum levels and the histological subtype and a variety of other parameters was investigated. In a subset of cases, immunohistochemical staining for CA19.9 was performed on tumour blocks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Serum CA19.9 levels were elevated in 27%, 38% and 40% of mucinous cystadenomas, borderline mucinous tumours and mucinous carcinomas, respectively. Markedly elevated levels of serum CA19.9 were observed in each group, with the highest serum CA19.9 measurements being noted in borderline mucinous tumours. There was no relationship between the serum CA19.9 level and whether the tumours were benign, borderline or malignant (Kruskal\u2013Wallis test p value=0.32). A weak but statistically significant correlation was found between tumour maximum dimension and CA19.9 level (Spearman's rank correlation coefficient=0.17, p=0.04). In those cases in which CA19.9 immunohistochemistry was performed, all tumours showed positive staining for CA19.9, with 60% of these cases being associated with an elevated serum CA19.9 level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Preoperative CA19.9 levels cannot be used to predict whether a suspected ovarian mucinous tumour is benign, borderline or malignant. Markedly elevated serum levels (&gt;1000\u2005U\/ml) may be found in benign mucinous neoplasms as well as in borderline and malignant tumours.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jcp.2009.072355","type":"journal-article","created":{"date-parts":[[2010,2,12]],"date-time":"2010-02-12T05:47:36Z","timestamp":1265953656000},"page":"169-173","source":"Crossref","is-referenced-by-count":56,"title":["Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype"],"prefix":"10.1136","volume":"63","author":[{"given":"Paul J","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooler","family":"Archbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Cardwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Glenn","family":"McCluggage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2010,2,12]]},"reference":[{"key":"2025092610092758000_63.2.169.1","unstructured":"Ballesta A Molina R . Tumor markers: definitions and classification. Torino: Edizioni Minerva Medica, 1993."},{"key":"2025092610092758000_63.2.169.2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/172460089801300402","article-title":"CA 125: the past and the future","volume":"13","author":"Bast","year":"1998","journal-title":"Int J Biol Markers"},{"key":"2025092610092758000_63.2.169.3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/"},{"key":"2025092610092758000_63.2.169.4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO;2-T"},{"key":"2025092610092758000_63.2.169.5","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(92)90030-M"},{"key":"2025092610092758000_63.2.169.6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"2025092610092758000_63.2.169.7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800301)45:5<948::AID-CNCR2820450519>3.0.CO;2-Q"},{"key":"2025092610092758000_63.2.169.8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901215)66:12<2628::AID-CNCR2820661227>3.0.CO;2-1"},{"key":"2025092610092758000_63.2.169.9","first-page":"667","article-title":"The clinical significance of elevated levels of serum CA 19-9","volume":"58","author":"Pavai","year":"2003","journal-title":"Med J Malaysia"},{"key":"2025092610092758000_63.2.169.10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/bjc.1985.161","article-title":"CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125","volume":"52","author":"Canney","year":"1985","journal-title":"Br J Cancer"},{"key":"2025092610092758000_63.2.169.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00284.x"},{"key":"2025092610092758000_63.2.169.12","first-page":"5","article-title":"Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients","volume":"43","author":"Dong","year":"2008","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"2025092610092758000_63.2.169.13","doi-asserted-by":"publisher","DOI":"10.1159\/000010062"},{"key":"2025092610092758000_63.2.169.14","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0191"},{"key":"2025092610092758000_63.2.169.15","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1995.1276"},{"key":"2025092610092758000_63.2.169.16","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1994.1044"},{"key":"2025092610092758000_63.2.169.17","first-page":"4","article-title":"Mucinous tumors of the ovary: a review","volume":"24","author":"Hart","year":"2005","journal-title":"Int J Gynecol Pathol"},{"key":"2025092610092758000_63.2.169.18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/00000478-200011000-00001","article-title":"Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with \u00e2\u0080\u0098pseudomyxoma peritonei\u00e2\u0080\u0099","volume":"24","author":"Lee","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"2025092610092758000_63.2.169.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpdhp.2008.06.010"},{"key":"2025092610092758000_63.2.169.20","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.049478"},{"key":"2025092610092758000_63.2.169.21","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000138178.10829.b8"},{"key":"2025092610092758000_63.2.169.22","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200202000-00001"},{"key":"2025092610092758000_63.2.169.23","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880115)61:2<340::AID-CNCR2820610225>3.0.CO;2-U"},{"key":"2025092610092758000_63.2.169.24","first-page":"182","article-title":"Borderline ovarian tumours: retrospective analysis of twenty-one cases","volume":"19","author":"Saygili","year":"1998","journal-title":"Eur J Gynaecol Oncol"},{"key":"2025092610092758000_63.2.169.25","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200212000-00001"},{"key":"2025092610092758000_63.2.169.26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00004347-199507000-00002","article-title":"Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and mullerian type","volume":"14","author":"Siriaunkgul","year":"1995","journal-title":"Int J Gynecol Pathol"},{"key":"2025092610092758000_63.2.169.27","doi-asserted-by":"publisher","DOI":"10.1007\/BF01542654"},{"key":"2025092610092758000_63.2.169.28","first-page":"228","article-title":"Tumor markers. Their current diagnostic status","volume":"138","author":"Kudlacek","year":"1988","journal-title":"Wien Med Wochenschr"},{"key":"2025092610092758000_63.2.169.29","first-page":"247","article-title":"Critical study of current tumoral markers","volume":"75","author":"Touitou","year":"1988","journal-title":"Bull Cancer"},{"key":"2025092610092758000_63.2.169.30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000293797","article-title":"Occurrence of CA 125 and CA 19-9 tumor-associated antigens in sera of patients with gynecologic, trophoblastic, and colorectal tumors","volume":"25","author":"Gocze","year":"1988","journal-title":"Gynecol Obstet Invest"},{"key":"2025092610092758000_63.2.169.31","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920415)69:8<2131::AID-CNCR2820690820>3.0.CO;2-A"},{"key":"2025092610092758000_63.2.169.32","first-page":"350","article-title":"The clinical utility of the CA 19-9 tumor-associated antigen","volume":"85","author":"Steinberg","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"2025092610092758000_63.2.169.33","doi-asserted-by":"publisher","DOI":"10.1080\/00016340701226138"},{"key":"2025092610092758000_63.2.169.34","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(92)90075-T"},{"key":"2025092610092758000_63.2.169.35","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199906000-00001"},{"key":"2025092610092758000_63.2.169.36","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19871115)60:10<2437::AID-CNCR2820601015>3.0.CO;2-K"},{"key":"2025092610092758000_63.2.169.37","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-200303000-00001"},{"key":"2025092610092758000_63.2.169.38","doi-asserted-by":"crossref","unstructured":"Scully RE Young R Clement P . Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Washington: Armed Forces Institute of Pathology, 1998.","DOI":"10.1097\/00004347-199907000-00019"},{"key":"2025092610092758000_63.2.169.39","first-page":"1579","article-title":"A case of metaplastic Brenner tumor with elevated serum CA19-9 levels","volume":"42","author":"Nishikawa","year":"1990","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi"},{"key":"2025092610092758000_63.2.169.40","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"2025092610092758000_63.2.169.41","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1174"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.2009.072355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:09:43Z","timestamp":1758906583000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.2009.072355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,2,12]]},"published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1136\/jcp.2009.072355"],"URL":"https:\/\/doi.org\/10.1136\/jcp.2009.072355","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}